Blood thinners therapy can decrease mortality in COVID patients:

        The full dosage of a normal thinner blood might stop blood clot formation and decrease the risk of serious disease and death by administering early to moderately sick hospitalised patients with the COVID-19, the study found.

       COVID-19 is characterised in the blood vessels and notably in the lungs with increased inflammation and improper coagulation and is thought to be contributing to severe illness and mortality growth.

The study conducted by researchers at St. Michael's Hospital in Canada and at the University of Vermont in the USA has shown that it stops clots and decreases inflammation, a blood thinner commonly used at the lowest dose for hospitalized patients. 

Mary Cushman, Medicine Professor, from the Vermont College of Medicine. "While this study is aimed to identify an impact on the primary outcome, including ICU transference, mechanical ventilation or death," Mary Cushman stated.

'Whereas the incidence of primary composites such as death, mechanical ventilation or ICU has not been statistically significantly less therapeutic heparin compared to the low dose heparin, the odds of Allcaus death with the therapeutic heparin were substantially reduced by 78 percent,' said first author Michelle Sholzberg, Head of Division of Hematology-Oncology, at St. Michael's Hospital of Unity Health Toronto, and assistant professor at the University of Toronto.

The researchers conducted an international randomised study examining the advantages for medical hospital patients admitted with COVID‐19 from providing an all therapeutic dosage of heparin vs a prophylactic low dose.

Four (1.8%) heparin patients died compared to 18 (7.6%) prophylactic heparin patients.

A subsequent pre-print meta-analysis indicated that therapeutic heparin is helpful for moderately sick patients, but not for seriously ill ICU patients.

Sholzberg stated: "We think that the outcomes of our study and the joint multi-platform test should lead to a change in clinical management for moderately diseased COVID-19 patients.